N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Mar 2022	46	Global Markets Direct	ASDR-599163

Published: Mar 2022 - Pages : 46 - Publisher : Global Markets Direct - Report code : ASDR-599163

Abeona Therapeutics Inc
Amicus Therapeutics Inc
ArmaGen Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
JCR Pharmaceuticals Co Ltd
Lysogene SAS
Tega Therapeutics Inc

N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2020

This report can be of interest as well:

N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2020

Published: August, 2020 | Report code: ASDR-563698